Qiagen, Gencurix announce oncology assay partnership

Qiagen (QGEN) and Gencurix announced a new partnership to develop oncology assays for use on the QIAcuityDx platform, a high-performance digital PCR system designed for clinical diagnostics. Gencurix is the first development partner under Qiagen’s QIAcuityDx Partnering Program. This important advancement marks a significant step towards establishing a broad menu of in vitro diagnostic assays on the QIAcuityDx Four platform, increasing access to digital PCR diagnostics. The new partnership combines Qiagen’s QIAcuityDx digital PCR platform to advance sensitive, cost-effective oncology diagnostics with Gencurix’s expertise in multiplex assay development. The aim is to enable the creation of oncology IVD assays for both tissue and liquid biopsy applications, with flexible commercialization options and global reach through Qiagen’s Partnering Program.